Sanofi (SNY) Reports FDA Review Accepted for Supplemental Biologics License Application for 0.5 mL Dose of Fluzone Quadrivalent (Influenza Vaccine) in Children 6-35 Months of Age
Tweet Send to a Friend
Sanofi (NYSE: SNY) announced the U.S. Food and Drug Administration has accepted for review a supplemental Biologics License Application to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE